Why are there two medications with the same ingredient?
Novo Nordisk originally developed semaglutide as a diabetes treatment (Ozempic, at lower doses). When they noticed significant weight loss in diabetes patients, they ran dedicated weight loss trials at a higher dose (2.4mg vs 1mg), leading to Wegovy's development and separate regulatory approval.
This is similar to how Viagra was originally developed for heart conditions but was separately approved for erectile dysfunction — same molecule, different dose, different approval.
Why was Ozempic restricted for weight loss?
Before Wegovy launched in Australia, Ozempic was widely prescribed "off-label" for weight loss. It was cheaper and more available. But this massive off-label demand created severe shortages for diabetes patients who genuinely needed it. The government intervened in October 2024, restricting new off-label weight loss prescriptions.
Which should you choose?
- If you have type 2 diabetes: Ozempic remains the best option — it's PBS-subsidised at ~$41/script and approved for your condition
- If you want weight loss medication: Wegovy is the correct choice — it's TGA-approved for weight management at the higher, more effective dose
- If you were on off-label Ozempic: Discuss switching to Wegovy with your doctor. You'll get a higher dose and proper weight management support
Can I switch from Ozempic to Wegovy?
Yes, and many patients are doing exactly this. Your doctor will typically transition you by continuing to increase the dose through the Wegovy escalation schedule. Since both contain semaglutide, the transition is relatively straightforward compared to switching between different drug classes.
Is Wegovy worth the extra cost?
Wegovy costs more than Ozempic on private prescription, but the higher dose means potentially more weight loss. If you're paying privately for weight management, Wegovy at the approved 2.4mg dose gives you the full therapeutic benefit — while Ozempic at 1mg is actually below the dose studied in weight loss trials.
If Wegovy gets PBS listed, the cost comparison reverses entirely — eligible patients would pay ~$31.60/script for Wegovy.